Hypertrophic Cardiomyopathy: Treatment, Risk Stratification, and Implantable Defibrillators by Magnusson, Peter
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 19
Hypertrophic Cardiomyopathy: Treatment, Risk
Stratification, and Implantable Defibrillators
Peter Magnusson
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/65392
Provisional chapter
Hypertrophic Cardiomyopathy: Treatment, Risk
Stratification, and Implantable Defibrillators
Peter Magnusson
Additional information is available at the end of the chapter
Abstract
Hypertrophic cardiomyopathy (HCM) affects  1:500 individuals,  and in majority of
cases, a mutation in sarcomere proteins can explain the disease. Phenotype is hetero‐
geneous and thus the prognosis. Many patients suffer from dyspnoea, especially at
exercise. Unfortunately, sudden cardiac death (SCD) does occur at all ages and is a major
cause of death in young adults. There is no proven pharmacological treatment to reduce
hypertrophy or  fibrosis,  but  beta‐blockers  are  first‐line  treatment.  In  patients  with
obstruction, myectomy is preferred in the young, but in older patients, alcohol septal
ablation is  tried to reduce symptoms and possibly prognosis.  Risk stratification of
sudden cardiac death is challenging. The major established risk factors are extreme
myocardial  thickness,  non‐sustained ventricular  tachycardia,  unexplained syncope,
abnormal exercise blood pressure response, and family history of sudden cardiac death.
In 2014, a novel risk calculator was developed that also takes age, outflow gradient, and
left atrial seize into account. Implantable defibrillator treatment is effective in HCM, but
complications requiring surgery and inappropriate shocks remain a problem.
Keywords: complications, hypertrophic cardiomyopathy, implantable defibrillator, in‐
appropriate shock, risk stratification, risk markers, sudden cardiac death
1. Diagnosis
Hypertrophic cardiomyopathy (HCM) implies increased ventricular thickness that is not only
a response to hypertension, aortic stenosis, or any other loading condition with abnormal
loading of the ventricle [1]. In adults, a wall thickness of ≥15 mm is typically required for
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diagnosis. In borderline cases (≥13 mm), a thorough evaluation including family history is
needed [1, 2]. In siblings, parents or children of a HCM patient, 13‐mm thickness is enough
for diagnosis [1, 2]. In children and adolescents, a wall thickness more than two standard
deviations in the corresponding age group should raise suspicion of the diagnosis of HCM [3].
An  ultrasound  of  the  heart,  echocardiography,  typically  reveals  the  diagnosis  of  HCM.
Echocardiography is usually readily available, but occasionally other imaging techniques are
needed. Cardiac magnetic resonance (CMR), computed tomography (CT) or rarely positron
emission tomography (PET) is sometimes used for diagnostic purposes or to gain additional
information for optimal disease management [4]. The hypertrophied segment is almost always
affecting the left ventricle even though right wall involvement does occur [1, 2]. Typically, the
septal part is enlarged, either the basal part or the middle part, but could affect lateral, posterior
and apical part, or a combination thereof [1]. A concentric hypertrophic is often associated
with secondary causes of hypertrophy but does occur as HCM entity. If an isolated hypertro‐
phy solely involves the basal part of the septal wall in an elderly and no other signs or family
history of HCM is found, often an explanation such as hypertension is the major cause [1, 2].
Even though the diagnosis of most cases of HCM is straight forward, careful attention to other
causes and robust imaging techniques, including a cardiologist with expertise in the field, is
warranted. Because HCM is a life‐long disease with consequences not only for the patient but
also for relatives, a correct diagnosis is indeed important.
2. Symptoms and signs
Dyspnoea is the predominant symptom of HCM that leads to evaluation with an echocardio‐
gram. Shortness of breath is pronounced at exertion due to relaxation disturbance of the left
ventricle during diastole and/or outflow tract obstruction. This latter form is called hypertro‐
phic obstructive cardiomyopathy, and the obstruction is often dynamic with regard to filling
pressure, heart rate and body position and affected by medications with effect on the cardio‐
vascular system. Often the patient has an adopted life style to decreased physical stamina, and
often the diagnostic presentation is rather vague including tiredness. The HCM diagnosis is
often delayed or sometimes misclassified from the initial diagnostic work‐up.
A progressive HCM may sometimes lead to deterioration of the systolic function of the left
ventricle. The ventricle dilates and hypertrophic segments remodel into dilatation, which
sometimes can make it difficult to discern from other cardiomyopathies with dilated mor‐
phology. This condition is called end stage and indicates a worse prognosis [5–8].
Chest pain without coronary disease may also lead the physician to evaluate alternative
diagnosis, and sometimes HCM is revealed. Microvascular dysfunction and fibrosis are part
of the disease progression; biopsies show myocardial disarray, and modern PET imaging
techniques confirm structural and functional abnormalities, which explain symptoms.
However, biopsies are not indicated as part of routine evaluation as the same information
would be gained non‐invasively [2, 4]. Syncope evaluation is sometimes the initial work‐up
that leads to the diagnosis of HCM. The mechanisms could be either hemodynamic or cardiac
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arrhythmias [9]. Less specific symptoms such as pre‐syncope, near‐syncope or vertigo will
often include ECG and that in turn will lead to suspicion of morphological disease.
Atrial fibrillation is common among HCM, and thus, the risk of embolization stroke warrants
effective anticoagulants even without other risk factors [10, 11]. The CHADSVASC score is not
validated for HCM patients, and current guidelines recommend warfarin/dual oral anticoa‐
gulants if no contraindication is present [2].
Unfortunately, the first manifestation of HCM could be sudden cardiac death (SCD). In such
cases, the autopsy confirms or at least suspects HCM even though the microscopy and post‐
mortem genetic evaluation will aid. A conclusive diagnosis of HCM is of uttermost importance
because of the inheritance pattern and relatives need to be evaluated.
3. Inheritance
In more than half of the HCM cases, modern genetic panels can explain the cause of HCM and
partly predict the outcome [12–14]. Of all mutations associated with HCM, the vast majority
affects myosin proteins: beta‐myosin heavy chain (MYH7) and myosin‐binding protein
(MYBPC3). Other components of the actin‐myosin filaments, such as troponins or tropomyo‐
sin, rarely explain disease [2]. However, there is a steady increase in disease causing mutations
due to increased research activities and widened genetic panels in everyday practise.
The mutations of HCM are autosomal dominant with the exception of the X‐linked Danon
disease due to lysosome‐associated membrane protein 2 [15]. The most common metabolic
disease causing hypertrophy of the heart is Anderson‐Fabry, which is a storage dysfunction
of the lysosomes. In children, hypertrophy of the heart is part of a syndrome, and constellations
of malformations may lead suspicion towards Noonans disease, LEOPARD or even more rare
diseases. In adults, amyloidosis should be part of the differential diagnosis. A correct molecular
diagnosis can sometimes provide clinicians with specific treatment options and thus improve
prognosis for the individual.
Family‐history taking is a compulsory part of the initial evaluation of a patient with a suspected
or conformed hypertrophy. The clinician should systematically document the patients’ report
on family members who died suddenly or suffered from unexplained syncope or other
symptoms suggesting an inheritance. This history taking may include not only first or
secondary degree relatives and but also often tedious and administrative efforts to search for
older documents, medical records, military service tests like ECG and autopsy protocols. In
families who have members who moved to other regions or emigrated from the country, this
can be especially challenging. A portion of detective abilities and a critical approach to
information from historical medical records or a patients’ explanation to a sudden death may
be unmasked by a pedigree of suspected HCM. In these efforts, a specialized health care
provider trained in history taking, administrative paths and updated knowledge of genetic
counselling including bioinformatics will be valuable in conjunction with the cardiologist.
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4. Epidemiology
Since the first descriptions of hypertrophy of the heart, numerous labels have been used [2,
16]. Still hypertrophic obstructive cardiomyopathy is frequently used, sometimes to stress that
an individual patient is symptomatic due to obstructive. While this can be illustrative in a case
eligible for septal reductive procedures such as myectomy or alcohol ablation, it can often
confuse health care providers, patients and relatives. Furthermore, since the dynamic state of
the disease, it can be difficult to assess even though guidelines provide support for establishing
degree of obstruction using pharmacological and physiological provocations of obstructive‐
ness. Nowadays, guidelines recommend the usage of HCM and avoid former nomenclature
[2].
In echocardiographic studies of populations in the USA, the prevalence of HCM is 1:500, which
has been confirmed in other geographical parts of the world with highly available resources
of diagnostic tools [17, 18]. Interestingly, also if patients without hypertrophy (phenotype) but
who have mutations associated with HCM (genotype), the prevalence is 1:350 [19]. This makes
HCM the most prevalent inherited myocardial disease. Because of the high prevalence, a basic
knowledge about the disease is needed among a broad spectrum of heath care providers and
managers.
The public awareness of HCM has been increased. This is probably due the journalistic
attention to sudden death among young people especially during sport activities. In fact, in
some countries and certain sport associations, screening of members of athletes is established.
However, the approach to screening has been a matter of controversies and the benefits
questioned and criticism of the resources it takes and the number of borderline cases that has
to be evaluated and managed [20–23].
Nevertheless, HCM or at least unexplained post‐mortem left ventricular hypertrophy is
considered the most common cause of sudden cardiac death among sport persons younger
than 35 years of age; HCM accounts for a half of the cases [24]. A historical perspective on this
topic found HCM as a major cause of sudden death in the young [25]. A recent study in
Denmark of all cases of SCD in the country reported a lower number [26]. From this Danish
cohort, the cases of HCM were further analysed with regard to medical attention before death
and about half of the cases had been evaluated for symptoms associated with HCM [26]. This
stresses the importance of a qualified disease management including risk stratification of
sudden cardiac death.
5. Pharmacological treatment
Recommendations of pharmacological treatment are based on smaller trials or empirical
findings on HCM patients or evidence from other patient groups. No drug has been proven
to reverse disease progression, but reduction in symptoms can often be achieved. Treatment
strategies are based on whether the patient suffers from left ventricular outflow tract obstruc‐
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tion or not. A peak gradient of ≥30 mmHg is considered as obstruction, but one should bear
in mind that this varies over time due to the hemodynamic situation [2].
The principle behind treatment options in patients with obstruction is to avoid severe dehy‐
dration with risk of low filling pressures, which could be deleterious for certain patients.
Therefore, dehydration, drugs with vessel dilatation actions, or increase in heart rate is
disadvantageous. Atrial arrhythmias are frequently encountered in HCM, and often a trigger
of unbearable symptoms leads the patient to hospitalization. If the patient is admitted within
48 hours or properly anticoagulated, direct electrical conversion is preferred. However, this is
often not the case. In such circumstances, beta‐blockers are the drug of choice and digoxin
should be avoided due to inotropic increase in myocardium [2].
The first‐line treatment option is beta‐blocking agents [2]. Notably, the beta‐blocker carvedilol
exerts vaso‐dilating effects and should be avoided. Historically, propranolol was used, but
nowadays metoprolol is often the drug of choice. Unfortunately, beta‐blockers commonly
imply side effects like cognitive impairment and exercise intolerance. This limit dosage
titration and compliance to the drug may be questioned. It is important to recognize side effects
and discuss alternatives rather than prompt withdrawal, which could possibly provoke
worsening of symptoms and cause arrhythmias due to rebound effects on beta‐receptors.
The calcium channel antagonist verapamil is often the drug of choice when beta‐blockers are
not reducing symptoms enough or not tolerated due to side effects. Diltiazem is an alternative
choice but not dihydropyridine calcium antagonists because of their vascular effects. Contra‐
indications of verapamil are systolic heart failure and conduction disturbances, i.e., bundle
branch block.
The class 1A drug disopyramide has been studied in HCM cohorts and may relieve obstructive
symptoms and are considered safe with regard to risk of ventricular arrhythmias. It can be
prescribed in addition to beta‐blockers. In practise, intolerance is frequent due to anticholi‐
nergic side effects (dry mucous membrane, urinary retention, and obstipation), and in some
countries, it is not available.
In patients without obstructive component of HCM, the same principle to diminish relaxation
disturbance of the left ventricle holds true. Loop diuretics and thiazides can be used without
the same precautions as in HCM with obstruction. If disease progression reaches the crossroad
with decreased systolic function with ejection fraction below 50%, treatment options include
the same drugs as in heart failure due to other causes: beta‐blockers, ACE/ARB‐inhibitors,
aldosterone receptor blockers, and diuretics.
6. Septal reduction therapy
In patients with symptoms due to pronounced obstruction (≥50 mmHg) despite pharmaco‐
logical treatment, invasive options remain. Myectomy requires open‐heart surgery and can be
performed concomitant mitral plasty or replacement [27]. The incision is typically up to 70 mm
and provides long‐term success even though complications, i.e., atrioventricular block, aortic
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valve insufficiency, septal shunts occur. Perioperative death is 1–4% and increase with age, left
atrial size, and female sex [28].
Alcohol septal ablation implies injection in an arterial branch with resulting necrosis and
decreased obstruction. It is less invasive but requires careful judgement of the targeted vessel
and still AV‐block complications in up to 20% of patients in some series and overall mortality
comparable to myectomy. Typically, alcohol ablation is the preferred method for older patients
and can be performed multiple times in the same patient. It is important to stress that the
decision to performed either alcohol septal ablation or myectomy should be done in centres
with expertise in the field and adequate volumes.
There has been a preference of myectomy over alcohol ablation in the USA compared to
Europe. The low number of myectomies in Europe has been criticized by experts [29].
Moreover, both myectomy and alcohol septal ablation result in scarring tissue, which have
been reported to be a substrate for ventricular arrhythmias have been a matter of debate.
However, in larger series, both methods seem to be safe at middle or long‐term follow‐ups
even if individual risk stratification is important even after successful septum reduction
procedure [30].
7. Pacemaker therapy
A pacemaker protects from bradycardia and is indicated in high degree AV‐block, tachy‐brady,
and occasionally to reduce outflow gradients in patient where options are not suitable [2, 31].
Ventricular pacing from the right apical part may relieve obstruction by an electrical dyssyn‐
chrony between septal and lateral segments of the left ventricle. Earlier studies showed
promising results, but current guidelines have constrained indications to include selected
patients described above [2, 31, 32]. In the case of indication of an implantable cardioverter
defibrillator (ICD) in patients with obstruction, patients should be considered for a dual
chamber system for this reason.
Cardiac resynchronization therapy (CRT) has evaluated in smaller observational trial of HCM
patients [33]. The experience is that it provides improved exercise capacity, functional class
and ejection fraction, and biomarker levels. The vast experience and solid scientific ground of
CRT treatment in patients with functional class II–IV, EF ≤ 35% despite optimal pharmacolog‐
ical treatment in left bundle branch block gives a rationale for usage in HCM patients with
end‐stage heart failure [31, 34, 35].
8. End-stage heart failure
Lowering EF is a predictor of worse outcome and is sometimes called ’burned‐out HCM.’ It is
important to recognize the beginning of this stage and take prompt action including optimal
pharmacologic treatments and device therapy. Notably, many patients have supernormal EF
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for several years, and when EF is below 50%, this is a turning point. An EF < 50% also predicts
risk of life threatening ventricular arrhythmias. This marks a risk for appropriate ICD therapy
and should thus imply consideration for preventing sudden cardiac death [34, 35].
If not CRT is enough in end‐stage heart failure due to HCM, the same approach as in life
threatening heart failure should apply. Rarely, very small left ventricular chamber cavity or
intractable ventricular arrhythmia situation without systolic dysfunction may be an indication.
Totally, 1–7% of all transplants have HCM as the indication [36]. Left ventricular assist devices
may be an option, and continuous axial flow assist therapy has shown promising results in a
small series [37].
9. Risk assessment
HCM is heterogeneous disease in many aspects including the risk of sudden cardiac death.
The combined risk of cardiovascular mortality is estimated to 6% per year [2]. The cardiovas‐
cular mortality constitutes heart failure, sudden cardiac death, and stroke. Many HCM cohorts
from highly specialized centres do not necessarily reflect the mortality of the whole HCM
population. In fact, a report with less selection bias reported a mortality of 2% [2]. In elderly
patients, above 65 years old, the mortality is similar to age‐ and sex‐matched population
according to US data [2]. However, sudden cardiac death does occur at all ages and is notably
high in early adulthood when sudden cardiac death otherwise is rare.
Survivors of cardiac arrest due to spontaneous ventricular fibrillation or sustained ventricular
tachycardia with hemodynamic compromise have 33% mortality at seven years or 41%
appropriate ICD therapy at five years [2, 38]. The survival after a cardiac arrest is approximately
10% in the general population. Because of the low chance of survival of cardiac arrest, these
patients need an ICD. Thus, these patients are eligible for ICDs as secondary prevention of
SCD, and the decision to implant is usually straight forward.
In patients who had not experienced a life threatening ventricular arrhythmia (primary
prevention), the decision to implant an ICD requires careful judgement of clinical risk markers
and consideration of comorbidities and risk of complications.
There have been three guidelines covering the complex task of ICD as primary prevention of
SCD; a joint guideline between the American College of Cardiology/American Heart Associ‐
ation and European Society of Cardiology from 2003, an updated guideline 2011 from
ACC/AHA and an ESC guideline launched in August 2014 [2, 39, 40]. The 2003 and 2011
guidelines provide readily evaluated risk factors from history taking, echocardiography and
exercise test. Often, one risk factor is considered enough for offering an ICD, but there are
differences between countries and centres. It has also not been conclusive if more than risk
factor actually correlates with increased risk of appropriate ICD therapy even though more
recent studies point in that direction. In addition, possible risk markers have been suggested
based on observational studies on ICD cohorts or case reports or expert opinions.
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According to guidelines from 2003 and 2011, five major risk factors are established: nonsus‐
tained ventricular tachycardia (NSVT), family history of sudden cardiac death (FHSCD),
abnormal blood pressure response (ABPRE), unexplained syncope, and MWT 30 mm. A meta‐
analysis from 2010 based on 30 articles confirmed these risk factors [41]. From this meta‐
analysis, the presence of left ventricular outflow tract obstruction showed convincing evidence
to support in association with SCD. There also seemed to be higher risk for younger patients
even though there is no age above which could be safe, but SCD occurs at all ages in HCM [2].
Atrial dilatation and subsequent atrial fibrillation also correlated with SCD in some studies [2].
In patients with concomitant coronary ischemic disease, there was possibly an additional risk
as well as in the small subset of patients with left ventricular apical aneurysms [2]. Genetic
factors are indirectly included because of the risk factor FHSCD but guideline stress phenotype
on an individual level; however, the presence of certain mutations, especially in the cases of
double or multiple mutations, there seemed to be an increased risk. ECG is abnormal in 90%
of HCM patients, and efforts have been made to correlate abnormalities to risk of SCD
suggesting QRS amplitudes and/or fragmentation as risk markers [2]. However, ECG pattern
has not been part of guidelines. SCD in athletes due to HCM is well known, and 2003 guideline
considered intense (competitive) physical exertion a possible risk factor [39]. Fibrosis assessed
on CMR has been studied is advocated as risk factor but is not yet part of guidelines [42, 43].
The evolving criticism on guidelines resulted in a completely new algorithm to assess 5‐year
risk of SCD in HCM [44]. The article preceding the guidelines change in August 2014 argued
that previous guideline considered the clinical parameters left ventricular hypertrophy as
binary (30 mm), and in the new guideline, it is treated as continuous [2]. They also included
age as the validation work was based on cohorts where risk was higher in the young. Atrial
enlargement was again considered a risk factor and included in the algorithm are treated as a
continuous variable. The new European algorithm is based on 3,675 patients from six centres
and follow‐up time of more than 24,000 patient years. One of the centres constituted an external
validation. Since the introduction of the 2014 ESC guidelines, external validation work has
been published [45]. These two reports support for using the new guidelines. The sophisticated
statistics behind the new guideline resulting in a formula with a prognostic index as an
exponential function have been overcome by an open access link where a clinician within a
few minutes can calculate 5‐year risk in an individual patient [2, 46]. However, one should
consider the aim of the new guidelines carefully and recognize its limitations. The authors of
the new algorithm considered the rationale for the new approach because previous guideline
would lead to overuse of ICD; many patients would experience harm of the ICD and never
have benefit of the device. One should bear in mind that the underlying patient cohorts were
adults and risk stratification in children and adolescent should be used with caution. Hyper‐
trophic as part of metabolic disease or syndromes were not part of study base. Paradoxically,
extreme left myocardial thickness 35 mm had low SCD risk, but this subset of patient was few
and the model does not seem to cover all ranges. Furthermore, the model does not take into
account the obstruction only at exercise but at rest.
Even though the new model has been widely recognized, it is still unclear to what degree it is
actually used globally. Recently, an independent assessment of the ESC risk model concluded
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that the model was unreliable because many patients with SCD or appropriate ICD therapy
had a low risk score. The implementation of new guidelines may take time or require further
refinement. Probably it will not replace previous strategies completely but serve as important
tool. Risk stratification is and will always be a complex task.
10. Age and gender
Most studies found no significant association with age and sudden death in HCM cohorts, but
these studies are typically ICD populations selected from tertiary centres [47]. Furthermore,
usually these studies do not take age- and sex-matched comparison with general population
into account. Many studies on ICD cohorts lack statistical power to detect differences at
different age strata. In two studies, there was an inverse relationship between age and sudden
cardiac death, but in the majority of studies, no association was demonstrated [2]. In a recently
published nationwide Swedish study without selection, bias age was not significantly associ-
ated with appropriate ICD therapy [34, 35]. In American guidelines, age is not part of risk
stratification, whereas in the European guidelines, age is part of the equation based on
validation of cohorts, which showed an increased risk in younger patients [2]. The association
between age and other risk factors is quite complicated, but there seems to be data supporting
the rationale for offering ICDs with NSVT, severe left ventricular hypertrophy (LVH) and
unexplained syncope in younger patients [2]. Age is further complicated by the individual
comorbidities and the discrepancy between biological and calendric age. From other guide-
lines on general ICD candidates, guidelines state at least 2 years of life expectancy to be eligible
for an ICD. An experienced clinician may reflect about age in the individual case but cannot
neglect local resources and risk of complications in addition to effective patient communication
on prognosis.
Most HCM cohorts have a majority of males. In the six cohorts in the ESC risk algorithm, the
proportion of males ranged from 59 to 72% (mean 64%) [2]. This pattern is also seen in several
ICD cohorts [34, 35, 47]. However, there does not seem to be a significant difference with regard
to risk of appropriate ICD therapy in these cohorts. It is important to recognize the individual
risk factor profile rather than gender itself. Neither previous nor current guidelines use gender
as part of risk stratification. Notably, females may have a higher risk for complications related
to the ICD system [47].
11. Nonsustained ventricular tachycardia (NSVT)
The presence of NSVT has been part on guidelines since it first appeared in 2003 after several
reports on the association to sudden cardiac death in HCM. This is in contrast to general ICD
population with ischemic or dilated CM with low EF in which NSVT is not part of guidelines
The definition of NSVT is at least three beats in a row of ventricular origin but varies with
regard to cycle length; the formal cut-off of 100 bpm is seldom used, and 120 or 150 bpm is
Hypertrophic Cardiomyopathy: Treatment, Risk Stratification, and Implantable Defibrillators
http://dx.doi.org/10.5772/65392
369
typically used [2]. The association of life threatening arrhythmias does not seem to vary with
length or cycle length. The maximal duration of NSVT is 30 seconds while longer duration is
called sustained ventricular tachycardia. The diagnosis of NSVT could be from an ambulatory
monitor such as Holter for 24–48 hours as prescribed in the evaluation of HCM patients.
However, sometimes NSVT is detected from telemetry in the ward or from a cardiac device,
i.e., a pacemaker EGM or implantable loop recorder. Interestingly, NSVT seems to be quite
common in ICD recipients. Thus, the more often a HCM patient is monitored for NSVT, the
higher the likelihood for detecting the risk factor NSVT. Prolonged monitoring with implant‐
able devices or non‐invasive ECG patches is currently not indicated without a history of
syncope but remains to be evaluated in the future.
12. Syncope
Syncope deserves special attention when it comes to interviewing the patient about the actual
episode. This includes observations from witness about duration (which often may be
overestimated) and signs before or after the loss of consciousness. Certain situations may be
typical for vaso‐vagal syncope (i.e., defection, micturition), situational or orthostatic hypoten‐
sion. Carotid sinus mechanism for syncope can sometimes be reproduced. The body position
and activity may aid important clues. If exercise‐induced syncope is experienced, this should
imply prompt evaluation because a malignant cause is likely. Notably, tiredness and seizure
may indicate epilepsy but do not rule out cardiac causes as severe cerebral hypoxia mimics
the clinical scenario. In some studies, unexplained syncope within six months seems to predict
worse outcome to higher extent [2]. Nevertheless, a syncopal episode suggestive or arrhythmic
cause independent of when it happened should warrant careful evaluation.
13. Family history
A family history of SCD is a dramatic event. Relatives of the victim have to deal with their own
attitude and subsequent risk assessment beside emotional impact of the lost relative. Unfortu‐
nately, not every physician is aware of the inheritance component in family of SCD or the family
does not seek medical advice due to this. Documentation from possibly related HCM is often
lacking, misinterpreted or unavailable. Current European guidelines state SCD in the first‐
degree relative before the age of 40, but no age cut‐off when SCD can be attributed to HCM [2].
The underlying studies are quite heterogeneous using different age limit. This risk factor is
further complicated as it does not take into account second‐ or third‐degree relatives nor the
number of siblings in a family. It is understandable that the motivation for patient and clinicians
is usually high when there is case of SCD in the family. However, the scientific basis is less
strong than for NSVT, unexplained syncope, or MWT, based on three studies, whereas several
other studies could not prove an association [2, 48]. If this inability is due to power problems
of studies because of the limited number of patients included and/or few outcome of events,
is difficult to judge. The heterogeneity of definitions and relative short follow‐up time may
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also influence the results. Statistical methods often account for uni‐ and multi‐variable
influence of risk factors but have difficulties to prove interaction between risk factors in smaller
samples with few events.
14. Wall thickness
In patients with a ≥30 mm maximal wall thickness, there was a three‐fold increased risk, which
makes it a comparatively strong risk factor. Later analyses suggest a U‐shaped correlation to
sudden cardiac death [49]. As mentioned above, this risk factor has been treated as binary risk
factor previously, at least theoretically, but in practise, it is likely that number patients have
been offered an ICD even if they did not fulfil this criterion formally. For example, in a 25‐year‐
old patient with otherwise long‐life expectancy, a 29 mm thickness would probably be enough
for most clinicians. Another limit is the fact that hypertrophy can be more or less unevenly
distributed, and it is not known if this influences risk. Moreover, echocardiography does not
always provide accurate estimations and certain parts, i.e., apical parts may be difficult to trace.
Other imaging techniques may resolve this problem in individuals. The progression of disease
is difficult to predict, but in a young patient, it is more likely and effect of hypertensive disease
is more easy to rule out. Future validation work on this risk factor will hopefully elucidate this
factor better. Here, CMR and PET may add important knowledge of not only structural
findings but also functional and metabolic disturbances associated with risk of arrhythmia.
15. Exercise blood pressure response
The assessment of this risk factor requires referral for ergometer bicycle test or any other
exercise test. In series of HCM patients, one third of patients show abnormal blood pressure
response [2, 50]. The definition of abnormal blood pressure response varies, but with regard
to risk stratification, a failure to increase systolic pressure at least 20 mmHg or a fall of 20
mmHg from peak pressure is considered relevant [2]. This risk factor seems to be more
pronounced in patients younger than 40 years old. In some studies, this risk factor has not been
analysed because not all patients were systematically assessed. This is understandable as if a
clinician already has data enough to support the decision to implant an ICD, there is a rationale
for omitting this test as is does not add clinical insight for further management of the individual
patient. In the new guidelines, the authors took the decision to abandon exercise test as part
of risk stratification, and it remains to be seen if upcoming guidelines will stick to this policy.
16. Atrial fibrillation and left atrial diameter
The increased filling pressures of the left ventricle will result in wall stress of left atrium and
risk of dilatation. There is a well‐known risk of atrial fibrillation and a dilated left atrium, and
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this in turn increases risk of embolic events. In a recent study, AF was a stronger risk factor
than the established five major risk factors in both univariable and multivariable analyses in
HCM‐ICD cohort [34, 35]. AF should be considered as a sole factor for risk stratification and
lead to an ICD, but in patients implanted based on the five major risk factors, AF predicted
high probability of appropriate ICD therapy [2, 34, 35].
Left atrial diameter is assessed by echocardiography using a parasternal projection and is now
part of the risk model algorithm [46]. It is handled as a continuous variable, but it does not
take into account the different shapes of the atrium as some patients have elongated atrium
mostly visualized in an apical four‐chamber view. Neither is the volume calculated, but a
simple diameter in one projection sometimes allows inter‐user variability and anatomical
variation difficult to standardize.
17. LVOT obstruction
The outflow gradient of the left chamber may vary and change with exercise or can be provoked
by drugs. In the meta‐analysis, they concluded that LVOT gradient should be reassessed as a
risk factor based on evidence from numerous observational studies [41, 51, 52]. This also holds
true when developing the new algorithm and was then included and treated as a continuous
variable.
18. CMR, CT and PET
Cardiac magnetic resonance using a contrast‐enhanced technique has demonstrated associa‐
tion with arrhythmias, and substantial amount of fibrosis may be suggestive increased risk for
SCD [53]. The accurate delineation and spatial resolution of CMR may aid in cases where
echocardiography is inadequate. However, to assess association between CMR‐derived
baseline data and outcome such as SCD or appropriate ICD therapy will follow‐up time and
large cohorts with enough events to prove association. Therefore, CMR has been included in
the first prospective registry on HCM patients, and this will hopefully provide gain of insight
in this matter. CMR uses magnetic fields instead of ionizing radiation, but contraindication
needs to be considered. Notably, ICD patients should be assessed before a device is implanted
even though newer ICD model may allow CMR at least 1.5 Tesla investigations but gives rise
to artefacts. PET can be used in conjunction within either CT or CMR and is a promising field
for research with functional, structural and metabolic assessment, which is available.
19. Driving
While most HCM patients have no driving restrictions, patients with ICD devices need special
considerations. This advice needs to be in harmony with national laws besides checking
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international guidelines that provide update recommendation on this topic. A survivor of
cardiac arrest should not drive for the first six months after the event, and careful assessment
of cognitive function is then advised. The same considerations should be made after stroke,
epilepsy, diabetes and other medical conditions. The risk after an arrhythmic event is highest
in the first few months, which makes six‐month restriction reasonably. In primary prevention
of ICD patients, there is no restriction except for unexplained syncope with a typical restriction
in the first 6 months. Professional driving (buss, truck, taxi) is not accepted for ICD carriers,
independent of indication (primary or secondary) in most countries. Other vehicles, including
trains and aeroplanes, need to be considered and legal actions taken.
20. Pregnancy
Pregnancy implies increased loading pressures, and in last semester, a cardiovascular demand
may increase risk. HCM is a heterogeneous disease, and risk of SCD during pregnancy needs
to be addressed based on individual factors. Few women need to give up a wish to become a
biological mother; however, there are fatal cases reported, but these have been in patients with
a known high risk. Because of the non‐negligible risk, females are advised to plan pregnancy
and counselling should be offered during the pregnancy and delivery by a multidisciplinary
team. In the rare case of need for ICD implant during pregnancy, efforts need to be taken to
provide protection from radiation or using echocardiography to assess position of leads.
21. Combinations of risk markers and modifiers
The new algorithm takes several risk factors into account and weights them using a formula
[46]. But even this method has the same lack of accurate estimation of mediating or possibly
protective interaction between markers. All markers are somewhat surrogates and life‐time
risk can never be exactly assessed in the individual. Long‐term follow‐up in all studies is
actually typically less than 10 years for the majority of the patient, and risk is not linear. Besides,
risk markers are assessed at the time for decision to implant and may change during the course
and should therefore be re‐assessed every 1–3 years. Again, a multicentre, international,
prospective registry will provide more insights in the challenge to stratify risk in HCM.
22. Children
Risk stratification in children equals adult strategy in many ways, but primary prevention is
typically based on two or more risk factors rather than one. Historically, epicardial lead has
been used in a growing child, but nowadays subcutaneous ICD may be a more attractive
option. A single device (ICD‐VVI) is usually sufficient as pacing indication is rare in the young,
and this approach seems to limit complications.
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23. ICD therapy
ICD is an effective way to prevent sudden cardiac death in HCM. The landmark trial by Maron
et al. demonstrated 11% annual rate in secondary and 5% annual rate in primary prevention
[54]. Several studies have confirmed the usefulness on ICD in HCM [47]. Schinkel et al.
performed a meta‐analysis of 2,190 patients from 16 cohorts (mean age 42 years, 62% males)
with 83% primary prevention indication [47]. The summary estimate for appropriate ICD
therapy was 3.3% per year (95% confidence interval 2.2–4.4%). A later nationwide ICD cohort
of unselected patients reported 4.5% appropriate ICD therapy in primary prevention and 7.0%
in secondary prevention [34, 35].
It should be noted that not every appropriate ICD therapy is indeed lifesaving. A ventricular
arrhythmia can self‐terminate, which can lead to an overestimation of benefit of ICD. There‐
fore, it is important to programme a number of intervals to at least 30 before therapy. The
detection zones should be carefully considered, and antitachycardia pacing (ATP) should be
used to avoid unnecessary shocks. However, the risk of a sustained ventricular below detection
zone could lead to fatal hemodynamic collapse including pulseless electrical tachycardia or
recurrent ventricular fibrillation when ventricles are finally exhausted. Patients on amiodarone
are known to have a slower rate than otherwise [2]. Earlier there have been worries about the
efficacy in hypertrophic heart due to increased myocardial mass to discharge, but large series
of a patient show efficacy of ICD discharges with very few exceptions. The discussion on DFT
testing preoperatively could be extended to HCM populations, but the trend to induce patients
more rarely, if at all, will continue for HCM patients. One may argue that induction is not
without risk; devices have high voltage and sufficient margin, and the clinical situation is not
exactly the same as during implant. Moreover, it may be advisable to choose a type and brand
of ICD device capable of wave form optimization and to deliver high voltage discharges.
Different devices offer different solutions to avoid T‐wave oversense, which should be reflected
upon. A T‐wave oversense leads to double counting and will deliver inappropriate shocks.
Technical failure of lead, fracture and insulation defects, or external noise could lead inappro‐
priate shocks. The overall annual risk of inappropriate shocks is 4.8% in a meta‐analysis [47]
and confirmed in later analyses of unselected populations [55]. Hopefully, with programming
optimization, this could likely be reduced. The most common cause of inappropriate shocks
is atrial arrhythmias, predominantly. In addition to programming longer duration, longer cycle
length, discrimination algorithm should be considered such as interval stability, but one should
neglect the risk of misdiagnosis simultaneous ventricular arrhythmias that need appropriate
therapy. Furthermore, other actions to avoid atrial tachycardia and to reduce rapid atrioven‐
tricular conduction are needed: beta‐blockers, antiarrhythmics, and occasionally His‐ablation.
Compared to other ICD populations where ATP is effective in a vast majority of cases, the
proportion of ATP success was less in HCM‐ICD cohorts. This has been seen in other HCM
trials, and HCM possibly carries an increased risk of rapid ventricular tachycardia or ventric‐
ular fibrillation to a larger extent than other ICD groups.
ICD systems offer an alert function for the patient if technical failure or essential clinical
episode takes place. Remote monitoring of ICD devices is standard, and this increases safety
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as it detects technical problems between follow‐ups in clinic or detects atrial fibrillation, which
implies decision to anticoagulated.
24. Death despite ICD
The efficacy of ICDs to prevent sudden cardiac death leads to a swift in cases of death. The
vast majority of death in the ICD population dies because of progressive heart failure. The
standardized mortality was 3.4 (95% confidence interval 2.4–4.5) compared to general popu‐
lation [56]. This implies that heart failure care needs to be addressed if improved survival
should be achieved. Importantly, a holistic approach to device patient is warranted, and one
should not just focus on the prevention of arrhythmia death.
25. Implant procedure
The procedure to implant an ICD in a HCM patient is essentially the same as in other indication.
The vascular access is typically from the left side either through cephalic cut‐down or punc‐
tures of the axillary or subclavian vein. The ventricular lead is implanted in the apical region
of the right ventricle if R‐waves and thresholds are acceptable in this position. It is important
to check for T‐wave oversensing before deciding the final position of the lead. In obstructive
HCM, it is of special importance to implant the lead in apex as this could facilitate reduction
in outflow gradient if AV‐pacing is tried. For the same reason, an atrial lead (ICD‐DR) is often
preferred. Furthermore, many HCM patients have high beta‐blocking dosage, conduction
defects or paroxysmal atrial fibrillation with the help of AV synchronous pacing. The ventricle
lead could be either single or dual coil. There is a tendency to increased use of single‐coil system
as possible defibrillation threshold difference is negligible, easier to implant and extract. The
device could be implanted subcutaneously or intramuscular. As described above, less number
of patients is induced nowadays. The typical procedure time is less than 1 hour, and the patient
can often be discharged the same day. The battery of an ICD in a modern system lasts for 8–
10 years, depending on amount pacing and, in few cases, the demand of therapies. CRT system
in end‐stage HCM has been tried with preliminary promising results.
26. Health-related quality of life
In a British study from 1995 on HCM patients, health‐related quality of life was decreased [57].
Since then, improvement of health care has been made, and there may be different outcomes
in a HCM population that is not selected from a specialized centre. Recently, a study on HCM
patients with ICDs confirmed poor quality of life, regardless of sex, age, or primary/secondary
indication [58]. Instead, atrial fibrillation and systolic heart failure are determinants of poor
quality of life, especially physical aspects. Notably, inappropriate, but appropriate therapies
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are associated with poorer mental health. To further address quality of life issues, qualitative
studies may provide valuable insights.
27. S-ICD
An subcutaneous‐ICD (S‐ICD) system contains a subcutaneously implanted lead (in an L‐
configuration) connected to a device inserted subcutaneously, or preferably intramuscular. It
effectively terminates ventricular arrhythmias and can offer supportive post‐chock pacing.
Current devices cannot be used in patients who need permanent pacing, but technical solutions
are developed to combine a leadless pacemaker system communicating with an S‐ICD system.
This is beneficial in patients with abnormal vascular anatomy, i.e., malformations or vessel
occlusions. But, in young patient, there is an increasing interest in S‐ICD to save vessels for
future interventions and avoid short‐term and long‐term vessel‐related complications. S‐ICD
has been used in HCM, but careful pre‐operative assessment of possibly risk of T‐wave
oversense is of importance in this group. The cost of S‐ICD device is currently much larger
than for transvenous device, but this probably diminishes. Studies so far have shown a
promising short‐term use of S‐ICD among HCM patients [59].
28. Future perspectives
There remain many challenges in the field of HCM. A detailed understanding of
pathophysiologic mechanism of disease progression, arrhythmia substrate and triggers and
molecular‐genetic base of the heterogeneous disease is crucial. This could lead to improvement
in the therapeutic arsenal, but this development relies on scientific progress in the field of
cardiology and basic sciences. Multicentre, prospective registries and other international
collaborations to evaluate outcome and refine risk stratification are promising [60, 61].
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